該雜志國(guó)際簡(jiǎn)稱(chēng):TECHNOL CANCER RES T,是由出版商SAGE Publications Inc.出版的一本致力于發(fā)布醫(yī)學(xué)研究新成果的的專(zhuān)業(yè)學(xué)術(shù)期刊。該雜志以O(shè)NCOLOGY研究為重點(diǎn),主要發(fā)表刊登有創(chuàng)見(jiàn)的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專(zhuān)論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。
《Technology In Cancer Research & Treatment》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊,中文名稱(chēng)癌癥研究與治療技術(shù),本刊主要出版、報(bào)道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專(zhuān)業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專(zhuān)業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為2.7,最新CiteScore 指數(shù)為4.4。
本刊近期中國(guó)學(xué)者發(fā)表的論文主要有:
ReRNet: A Deep Learning Network for Classifying Blood Cells
Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study
Technology in Cancer Research & Treatment (TCRT)?is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.
中科院SCI分區(qū)
Technology In Cancer Research & Treatment雜志中科院分區(qū)信息